001     276938
005     20240229155007.0
024 7 _ |a 10.1186/s12885-023-11056-1
|2 doi
024 7 _ |a pmid:37337133
|2 pmid
024 7 _ |a altmetric:150312328
|2 altmetric
037 _ _ |a DKFZ-2023-01215
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Christakoudi, Sofia
|b 0
245 _ _ |a A body shape index (ABSI) is associated inversely with post-menopausal progesterone-receptor-negative breast cancer risk in a large European cohort.
260 _ _ |a Heidelberg
|c 2023
|b Springer
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1687357353_6280
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Associations of body shape with breast cancer risk, independent of body size, are unclear because waist and hip circumferences are correlated strongly positively with body mass index (BMI).We evaluated body shape with the allometric 'a body shape index' (ABSI) and hip index (HI), which compare waist and hip circumferences, correspondingly, among individuals with the same weight and height. We examined associations of ABSI, HI, and BMI (per one standard deviation increment) with breast cancer overall, and according to menopausal status at baseline, age at diagnosis, and oestrogen and progesterone receptor status (ER+/-PR+/-) in multivariable Cox proportional hazards models using data from the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort.During a mean follow-up of 14.0 years, 9011 incident breast cancers were diagnosed among 218,276 women. Although there was little evidence for association of ABSI with breast cancer overall (hazard ratio HR = 0.984; 95% confidence interval: 0.961-1.007), we found borderline inverse associations for post-menopausal women (HR = 0.971; 0.942-1.000; n = 5268 cases) and breast cancers diagnosed at age ≥ 55 years (HR = 0.976; 0.951-1.002; n = 7043) and clear inverse associations for ER + PR- subtypes (HR = 0.894; 0.822-0.971; n = 726) and ER-PR- subtypes (HR = 0.906; 0.835-0.983 n = 759). There were no material associations with HI. BMI was associated strongly positively with breast cancer overall (HR = 1.074; 1.049-1.098), for post-menopausal women (HR = 1.117; 1.085-1.150), for cancers diagnosed at age ≥ 55 years (HR = 1.104; 1.076-1.132), and for ER + PR + subtypes (HR = 1.122; 1.080-1.165; n = 3101), but not for PR- subtypes.In the EPIC cohort, abdominal obesity evaluated with ABSI was not associated with breast cancer risk overall but was associated inversely with the risk of post-menopausal PR- breast cancer. Our findings require validation in other cohorts and with a larger number of PR- breast cancer cases.
536 _ _ |a 313 - Krebsrisikofaktoren und Prävention (POF4-313)
|0 G:(DE-HGF)POF4-313
|c POF4-313
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a ABSI
|2 Other
650 _ 7 |a Body shape
|2 Other
650 _ 7 |a Breast cancer
|2 Other
650 _ 7 |a Hip size
|2 Other
650 _ 7 |a Obesity
|2 Other
650 _ 7 |a Waist size
|2 Other
650 _ 7 |a Progesterone
|0 4G7DS2Q64Y
|2 NLM Chemicals
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Body Mass Index
|2 MeSH
650 _ 2 |a Breast Neoplasms: complications
|2 MeSH
650 _ 2 |a Risk Factors
|2 MeSH
650 _ 2 |a Progesterone
|2 MeSH
650 _ 2 |a Prospective Studies
|2 MeSH
650 _ 2 |a Triple Negative Breast Neoplasms: complications
|2 MeSH
650 _ 2 |a Postmenopause
|2 MeSH
650 _ 2 |a Somatotypes
|2 MeSH
700 1 _ |a Tsilidis, Konstantinos K
|b 1
700 1 _ |a Dossus, Laure
|b 2
700 1 _ |a Rinaldi, Sabina
|b 3
700 1 _ |a Weiderpass, Elisabete
|b 4
700 1 _ |a Antoniussen, Christian S
|b 5
700 1 _ |a Dahm, Christina C
|b 6
700 1 _ |a Tjønneland, Anne
|b 7
700 1 _ |a Mellemkjær, Lene
|b 8
700 1 _ |a Katzke, Verena
|0 P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4
|b 9
|u dkfz
700 1 _ |a Kaaks, Rudolf
|0 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a
|b 10
|u dkfz
700 1 _ |a Schulze, Matthias B
|b 11
700 1 _ |a Masala, Giovanna
|b 12
700 1 _ |a Grioni, Sara
|b 13
700 1 _ |a Panico, Salvatore
|b 14
700 1 _ |a Tumino, Rosario
|b 15
700 1 _ |a Sacerdote, Carlotta
|b 16
700 1 _ |a May, Anne M
|b 17
700 1 _ |a Monninkhof, Evelyn M
|b 18
700 1 _ |a Quirós, J Ramón
|b 19
700 1 _ |a Bonet, Catalina
|b 20
700 1 _ |a Sánchez, Maria-Jose
|b 21
700 1 _ |a Amiano, Pilar
|b 22
700 1 _ |a Chirlaque, María-Dolores
|b 23
700 1 _ |a Guevara, Marcela
|b 24
700 1 _ |a Rosendahl, Ann H
|b 25
700 1 _ |a Stocks, Tanja
|b 26
700 1 _ |a Perez-Cornago, Aurora
|b 27
700 1 _ |a Tin Tin, Sandar
|b 28
700 1 _ |a Heath, Alicia K
|b 29
700 1 _ |a Aglago, Elom K
|b 30
700 1 _ |a Peruchet-Noray, Laia
|b 31
700 1 _ |a Freisling, Heinz
|b 32
700 1 _ |a Riboli, Elio
|b 33
773 _ _ |a 10.1186/s12885-023-11056-1
|g Vol. 23, no. 1, p. 562
|0 PERI:(DE-600)2041352-X
|n 1
|p 562
|t BMC cancer
|v 23
|y 2023
|x 1471-2407
909 C O |o oai:inrepo02.dkfz.de:276938
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 9
|6 P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 10
|6 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-313
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Krebsrisikofaktoren und Prävention
|x 0
914 1 _ |y 2023
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-03-30
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-03-30
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2023-03-30
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2023-03-30
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b BMC CANCER : 2022
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2023-05-21T15:34:55Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2023-05-21T15:34:55Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Open peer review
|d 2023-05-21T15:34:55Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2023-10-24
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2023-10-24
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2023-10-24
920 1 _ |0 I:(DE-He78)C020-20160331
|k C020
|l C020 Epidemiologie von Krebs
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C020-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21